Divi’s Laboratories – Q1 FY27 EARNINGS CALL HIGHLIGHTS
#Q1FY27
Management Commentary
– Strong execution continued.
– Custom synthesis accelerated.
– Generic business remained resilient.
– Peptides remained strategic priority.
– Capex projects nearing completion.
– Backward integration strengthened.
– Manufacturing reliability improved.
– Double-digit growth outlook maintained.
Financial Performance
– Total Income: ₹3,144 Cr (+24% YoY).
– PAT: ₹902 Cr (+66% YoY).
– PBT: ₹1,180 Cr (+61% YoY).
– Exports: 90% of revenue.
– Custom Synthesis: 60% mix.
– Generics: 40% mix.
– Nutraceutical Revenue: ₹298 Cr (+19%).
– Cash & Equivalents: ₹3,611 Cr.
Business Performance
– Generic volumes remained stable.
– Pricing stayed competitive.
– Peptide pipeline expanded.
– Multiple customer validations ongoing.
– Three major projects validating.
– 20 commercial CDMO projects.
– Europe & North America dominant.
– Backward integration enhanced.
Growth Initiatives
– Peptide capacity expanding.
– Additional SPPS reactors planned.
– Continuous flow chemistry adopted.
– Biocatalysis capabilities strengthened.
– Automation investments continued.
– Green chemistry initiatives expanded.
– Process intensification progressing.
– Unit-3 role increasing.
Operational Highlights
– Three-month inventory strategy.
– Unit utilization: 80–85%.
– ₹451 Cr assets capitalized.
– CWIP: ₹2,034 Cr.
– Three capex projects ~70% complete.
– Raw material sourcing diversified.
– Logistics managed efficiently.
– Technology capabilities strengthened.
Management Guidance
– Double-digit revenue growth.
– Custom synthesis momentum sustained.
– Commercial supplies after approvals.
– Peptide investments to continue.
– Margins to remain quarterly volatile.
– Annual margin focus maintained.
– Validation pipeline progressing.
– Long-term growth outlook positive.
Key Positives
– Strong earnings growth.
– Robust custom synthesis.
– Healthy cash position.
– Expanding peptide platform.
– Integrated manufacturing advantage.
– Capex nearing completion.
– Stable generic business.
– Strong customer pipeline.
– Supply chain resilience.
– Backward integration benefits.
Key Challenges
– Solvent cost inflation.
– Geopolitical uncertainty.
– Logistics disruptions.
– Elevated freight costs.
– Raw material volatility.
– Regulatory approval timelines.
– Quarterly revenue lumpiness.
– Customer confidentiality restrictions.
Management Tone
– Highly confident.
– Execution-focused.
– Long-term optimistic.
– Growth-oriented.
Key Takeaway
– Divi’s Laboratories is entering its next growth phase, supported by strong custom synthesis momentum, expanding peptide capabilities, integrated manufacturing, and multiple late-stage customer programs, while maintaining a disciplined long-term execution strategy despite near-term supply chain volatility.
Clean Science & Technology – Q1 FY27 EARNINGS CALL HIGHLIGHTS
#Q1FY27
Management Commentary
– Record quarterly sales achieved.
– HALS business scaling strongly.
– Supply chain challenges persisted.
– Demand environment remained stable.
– Product mix improved.
– Strategic partnerships announced.
– Commercialization milestones progressing.
– Long-term outlook remained positive.
Financial Performance
– Consolidated Revenue: ₹264 Cr (+10% YoY).
– Standalone Revenue: ₹203 Cr (+5% QoQ).
– Standalone EBITDA: ₹87 Cr.
– Standalone EBITDA Margin: 43%.
– Standalone PAT: ₹73 Cr.
– Consolidated EBITDA: ₹96 Cr.
– Consolidated EBITDA Margin: 37%.
– Consolidated PAT: ₹73 Cr.
Business Performance
– HALS: 22% of sales.
– HALS exports: ~50% of sales.
– HALS volume: ~1,000 MT.
– HALS realization improved.
– Legacy demand remained steady.
– Performance Chemicals: 83% mix.
– Pharma: 10% mix.
– FMCG: 7% mix.
Growth Initiatives
– Swiss Genius Kem partnership.
– Advanced NOR HALS launch.
– Joint global marketing planned.
– Hydroquinone plant ramping up.
– Performance Chemical-2 in Q3.
– Kemin five-year agreement signed.
– Export penetration increasing.
– Higher-grade HALS expansion.
Operational Highlights
– Highest-ever quarterly sales.
– CFCL became self-sustaining.
– HALS export mix diversified.
– ₹100 Cr infused into CFCL.
– Total CFCL investment: ₹850 Cr.
– Higher-grade HALS increasing.
– Customer approvals received.
– Commercial ramp-up underway.
Management Guidance
– HALS Revenue: ₹250–300 Cr FY27.
– Performance Chemical-2: Q3 FY27.
– Hydroquinone revenues to rise.
– EBITDA margins to improve.
– Higher-grade HALS mix increasing.
– New HALS plant: Q3 FY27.
– Supply chain normalization expected.
– Long-term growth remains strong.
Key Positives
– Record quarterly revenue.
– Strong HALS growth.
– Improving product mix.
– Premium export expansion.
– Swiss technology partnership.
– Five-year Kemin agreement.
– Higher operating leverage.
– Margin improvement potential.
– Strong customer approvals.
– Diversified revenue profile.
Key Challenges
– Raw material inflation.
– Middle East disruptions.
– Freight cost pressures.
– Vessel availability issues.
– Export logistics delays.
– Limited pricing pass-through.
– China cost advantage.
– Commodity volatility.
Management Tone
– Highly confident.
– Growth-focused.
– Execution-driven.
– Optimistic.
Key Takeaway
– Clean Science is entering its next growth phase, driven by rapid HALS scale-up, premium product expansion, strategic global partnerships, and improving operating leverage, while navigating temporary supply chain and raw material headwinds.
Muthoot Finance – Q1 FY27 EARNINGS CALL HIGHLIGHTS
#Q1FY27
Management Commentary
– Strong FY27 start.
– Gold loan demand robust.
– Market leadership sustained.
– Regulatory changes positive.
– Customer franchise strengthened.
– Asset quality remained strong.
– Growth momentum continued.
– Long-term outlook confident.
Financial Performance
– Consolidated AUM: ₹1.91 Lakh Cr (+43% YoY).
– Standalone AUM: ₹1.72 Lakh Cr (+43% YoY).
– Consolidated PAT: ₹2,825 Cr (+43% YoY).
– Standalone PAT: ₹2,550 Cr (+25% YoY).
– Standalone Income: ₹7,603 Cr (+33% YoY).
– ROA: 6.09%.
– ROE: 26.6%.
– Capital Adequacy: 20.3%.
Business Performance
– Gold Loan AUM: ₹1.75 Lakh Cr.
– Standalone Gold AUM: ₹1.63 Lakh Cr.
– 4.82 lakh new customers added.
– Active customers: 65.77 lakh.
– 1.63 lakh active additions.
– Branch productivity improved.
– Gold AUM/Branch: ₹32.47 Cr.
– Credit Loss: 0.05%.
Growth Initiatives
– 86 group branches added.
– Digital omni-channel expansion.
– New gold loan products.
– Higher LTV offerings launched.
– Income-generating loans planned.
– Belstar gold loans expanding.
– Northern markets scaling.
– Customer acquisition strengthened.
Operational Highlights
– Group branches: 7,654.
– Yield normalized to 17.93%.
– Target yield: 18–18.5%.
– Flexible repayment schemes.
– 85% LTV products launched.
– Auctions remained negligible.
– Compliance framework strengthened.
– Operational efficiency improved.
Management Guidance
– AUM guidance under review.
– Yield: 18–18.5% expected.
– Strong AUM growth ahead.
– Guidance review after H1.
– Gold loan demand healthy.
– Continue branch expansion.
– Focus on customer retention.
– Maintain superior asset quality.
Key Positives
– Strong AUM growth.
– Healthy profitability.
– Best-in-class ROA.
– Excellent asset quality.
– Expanding customer base.
– Strong capital adequacy.
– Regulatory formalization benefits.
– Branch productivity improving.
– Subsidiaries performing well.
– Gold loan demand resilient.
Key Challenges
– Yield compression.
– Rising competition.
– Lower lending rates.
– Product repricing.
– Customer education required.
– Competitive intensity increasing.
– Funding cost pressure.
– Margin normalization.
Management Tone
– Highly confident.
– Customer-focused.
– Growth-oriented.
– Optimistic.
Key Takeaway
– Muthoot Finance remains well-positioned to capitalize on India’s growing gold loan opportunity through its trusted franchise, expanding distribution, superior asset quality, and disciplined execution, while accepting moderate yield compression to sustain long-term growth.
Read More:
Read More article like this on sharepricenews.com
